Evidena Care, one of Switzerland’s leading specialised telemedicine providers for medical cannabis, has announced the launch of a nationwide online comparison platform for prescription-based medical cannabis products.
As the first large-scale Swiss telemedical company focused exclusively on cannabinoid therapies, Evidena Care currently supports more than 3,000 patients across Switzerland. Under the leadership of Dr Nicolai Berardi and a team of three specialised physicians, the company has achieved sustained monthly growth of approximately 10% over the past two years, positioning itself as a key infrastructure player in the rapidly evolving Swiss medical cannabis market.
The newly launched platform integrates product and price data from all relevant Swiss pharmacies, providing a structured and transparent overview of available medical cannabis products, formulations, and cannabinoid concentrations (THC/CBD), alongside direct price comparisons.
Strategic Market Positioning
The Swiss medical cannabis market remains highly fragmented, with significant price discrepancies between pharmacies for comparable products and identical active ingredient concentrations. As reimbursement by health insurers is often limited or unavailable, pricing transparency represents a structural inefficiency within the current system.
By integrating a comprehensive comparison engine directly into its telemedical ecosystem, Evidena Care expands beyond clinical service provision and positions itself as a transparency-driven market enabler. The platform aggregates product and pricing data from leading Swiss pharmacies, enables structured comparison of formulations and cannabinoid profiles, improves cost efficiency within prescription-based therapies, and encourages competitive pricing within a regulated medical framework.
From Telemedicine Provider to Digital Healthcare Infrastructure
Through its integrated digital model, Evidena Care combines specialised telemedical consultation, prescription management, and nationwide product and price transparency — positioning the company not only as a healthcare provider, but as a scalable digital infrastructure platform within Switzerland’s cannabinoid therapy segment.
“Transparent pricing and structured market access are essential for the long-term credibility and sustainability of medical cannabis in Switzerland,” said Dr Nicolai Berardi, CEO of Evidena Care. “Our comparison platform introduces transparency at scale and strengthens fair competition while maintaining strict medical oversight.”
Growth Outlook
With a rapidly expanding patient base, consistent monthly growth of approximately 10%, and a lean physician-led operating structure, Evidena Care is strategically positioned to capitalise on:
- Increasing physician acceptance of cannabinoid-based therapies
- Growing patient demand for alternative and personalised treatment options
- Regulatory normalisation of medical cannabis in Switzerland
- Continued digital transformation of healthcare delivery
The launch of the comparison portal represents a strategic milestone in Evidena Care’s evolution — reinforcing its role as Switzerland’s leading telemedical platform for prescription-based medical cannabis and setting new standards for transparency, efficiency, and digital integration in the sector.
